[Treatment of dermatological cases with BB-K8 (author's transl)].
Twenty-seven cases were treated with BB-K8, a new derivative of kanamycin acylated with l-(-)-gamma-amino-alpha-hydroxybutyric acid at the C-1 amino group of the 2-deoxystreptamine moiety. The majority of them were acute primary pyoderma and acute secondary pyoderma. BB-K8 was effective in 23 cases (85.2%) out of 27 cases treated and no side effect was encountered. BB-K8 had antibacterial activity against not only Staphylococcus but also Pseudomonas and Klebsiella. Thus, BB-K8 was considered to be effective in acute pyodermic condition.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000583:Amikacin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002675:Child, Preschool; D004341:Drug Evaluation; D004891:Erythema Induratum / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D005667:Furunculosis / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D007223:Infant; D007612:Kanamycin / Q000031:analogs & derivatives*; D008297:Male; D010201:Panniculitis, Nodular Nonsuppurative / Q000188:drug therapy; D003668:Pressure Ulcer / Q000188:drug therapy / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000302:isolation & purification; D012874:Skin Diseases, Infectious / Q000188:drug therapy; D013210:Staphylococcus / Q000187:drug effects / Q000302:isolation & purification
D007612:Kanamycin; D000583:Amikacin